Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Heart Failure 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

pembrolizumab 13Nivolumab 6Cyclophosphamide 6Carboplatin 6Specimen Handling 5Pemetrexed 5Paclitaxel 5Docetaxel 5Cisplatin 5Cetuximab 5Bevacizumab 5fludarabine phosphate 4fludarabine 4atezolizumab 4tislelizumab 3durvalumab 3Standard of Care 3Practice Guidelines as Topic 3Methods 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Gemcitabine 3Educational Status 3Early Intervention, Educational 3130-nm albumin-bound paclitaxel 3venetoclax 2tremelimumab 2temsirolimus 2niraparib 2ixazomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × empagliflozin × 30 days × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡